Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate and compare the OS of subjects with advanced or metastatic HER2 negative breast cancer when treated with ruxolitinib in combination with capecitabine versus capecitabine alone.
Critère d'inclusion
- Metastatic or advanced HER-2 negative breast cancer patients who have already received treatment with anthracyclines and paclitaxel